The research compound in Victoza^®

Victoza^® is a type 2 diabetes medicine from Novo Nordisk. Its active compound is Liraglutide — which is what this catalogue supplies, as a research material.

This is not Victoza^®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Liraglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Victoza^® is a trademark of Novo Nordisk, referenced here only to identify the compound.

Victoza is the brand under which liraglutide is marketed for type 2 diabetes. The same compound is sold as Saxenda for weight management.

It was among the first GLP-1 agonists engineered for extended action through fatty-acid acylation, a design principle later taken further by semaglutide.

The compound is listed here as a research material, not as the branded medicine.

Liraglutide in this catalogue

Other brands using Liraglutide

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.